Evidence map›Paper›PMID 28371892›Full record

ArticleNeuro-oncology2017

Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.

Xuechao Wu, Yingyi Wang, Tianfu Yu, Er Nie, Qi Hu, Weining Wu, Tongle Zhi, Kuan Jiang, Xiefeng Wang, Xiaojie Lu and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Advancing Ischemic Stroke Prognosis: Key Role of MiR-155 Non-Coding RNA.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Microglia and Brain Macrophages as Drivers of Glioma Progression.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xuechao WuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Yingyi WangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Tianfu YuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Er NieDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Qi HuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Weining WuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Tongle ZhiDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Kuan JiangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Xiefeng WangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Xiaojie LuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Hailin LiDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Ning LiuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Junxia ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Yongping YouDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMIR155 host gene (MIR155HG) is a long noncoding RNA that has been considered as the primary micro (mi)RNA of miR-155. MIR155HG plays an essential role in hematopoiesis, inflammation, and tumorigenesis. Our study investigated the clinical significance, biological function, mechanisms, and small-molecule inhibitors of the MIR155HG/miR-155 axis in glioma.

methodsWe analyzed the expression of the MIR155HG/miR-155 axis and the correlation with glioma grade and patient survival using 2 different glioma gene expression datasets. Biological significance was elucidated through a series of in vitro and in vivo experiments. Furthermore, we conducted a high-throughput screening for small molecules to identify a potential inhibitor of the MIR155HG/miR-155 axis.

resultsIncreased MIR155HG was associated with glioma grade, mesenchymal transition, and poor prognosis. Functionally, MIR155HG reduction by small interfering RNA inhibited cell proliferation, migration, invasion, and orthotopic glioma growth by repressing the generation of its derivatives miR-155-5p and miR-155-3p. Bioinformatics and luciferase reporter assays revealed that protocadherin 9 and protocadherin 7, which act as tumor suppressors by inhibiting the Wnt/β-catenin pathway, were direct targets of miR-155-5p and miR-155-3p, respectively. Finally, we identified NSC141562 as a potent small-molecule inhibitor of the MIR155HG/miR-155 axis.

conclusionsOur results demonstrate that the MIR155HG/miR-155 axis plays a critical role in facilitating glioma progression and serves as a prognostic factor for patient survival in glioblastoma. High-throughput screening indicated that the MIR155HG/miR-155 axis inhibitor NSC141562 may be a useful candidate anti-glioma drug.

Indexed as

AnimalsAntineoplastic AgentsBiomarkers, TumorBrain NeoplasmsCell SurvivalEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticGliomaHeterograftsHumansKaplan-Meier EstimateMiceMice, NudeMicroRNAsProportional Hazards ModelsAntineoplastic AgentsBiomarkers, TumorMicroRNAsMIRN155 microRNA, humangliomamesenchymal transitionMIR155HGsmall-molecule inhibitorsurvival

Identifiers

PMID28371892
PMCPMC5570208
OpenAlexW2602182609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.